HBM Healthcare Investments : Raptor Pharmaceuticals Acquires Rights to QuinsairTM

Media Release

Zug, 21 August 2015

Raptor Pharmaceuticals (NASDAQ: RPTP) announced the acquisition of the rights to the inhalable antibiotic QuinsairTM yesterday. Under the terms of the agreement, Raptor will pay USD 68.4 million upfront (of which up to USD 34.2 million in shares) as well as contingent milestone payments of up to USD 350 million plus single-digit royalties on global net sales. The milestone payments can partially be made in Raptor common stock.
QuinsairTM, an inhaled antibiotic for patients with cystic fibrosis, was developed by the former HBM- portfolio company Mpex Pharmaceuticals. Mpex was acquired by Axcan Pharmaceuticals (now a subsidiary of Allergan) in April 2011. As a result of a series of acquisitions thereafter, the rights to QuinsairTM went back to the original shareholders of Mpex. The product was approved in March 2015 for the European and in June 2015 for the Canadian market.
HBM Healthcare Investments will receive approximately USD 8 million from the upfront payment in the form of cash and shares and participates with around 13 percent on the future milestone payments and royalties. On the basis of a prudent assessment of the transaction, the net asset value (NAV) per HBM-share increases by around CHF 0.90.
For further information, please contact Dr. Andreas Wicki, tel.: +41 41 768 11 08, andreas.wicki@hbmhealthcare.com

HBM Healthcare Investments actively invests in the human medicine, biotechnology, medical technology and diagnostics sectors, and related areas. The company holds and manages an international portfolio of some twenty five promising companies. Many of these companies have their lead products already available on the market or at an advanced stage of development. The focus of investment is on follow-on financing for existing portfolio companies. These portfolio companies are closely tracked and actively guided on their strategic directions. This is what makes HBM
Healthcare Investments an interesting alternative to investing in big pharma and biotech companies.

Bundesplatz 1 CH-6300 Zug | Tel: +41 41 768 11 08 | Fax: +41 41 768 11 09 | info@hbmhealthcare.com www.hbmhealthcare.com

HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss
Exchange (ticker: HBMN).

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (Wertpapierprospektgesetz). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM Healthcare Investments Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities

legislation.

Bundesplatz 1 CH-6300 Zug | Tel: +41 41 768 11 08 | Fax: +41 41 768 11 09 | info@hbmhealthcare.com www.hbmhealthcare.com

distributed by